Trials / Completed
CompletedNCT04317040
Efprezimod Alfa (CD24Fc, MK-7110) as a Non-antiviral Immunomodulator in COVID-19 Treatment (MK-7110-007)
A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 234 (actual)
- Sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the efficacy and safety of efprezimod alfa in hospitalized adult participants who are diagnosed with coronavirus disease 2019 (COVID-19) and receiving oxygen support. The primary hypothesis of the study is clinical improvement in the experimental group versus the control group.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Efprezimod alfa | Efprezimod alfa is given on Day 1. |
| DRUG | Placebo | Placebo is given on Day 1. |
Timeline
- Start date
- 2020-04-24
- Primary completion
- 2020-10-20
- Completion
- 2020-10-20
- First posted
- 2020-03-20
- Last updated
- 2023-02-08
- Results posted
- 2021-10-15
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04317040. Inclusion in this directory is not an endorsement.